- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02919787
Nordic Pancreatic Cancer Trial (NorPACT) - 1
Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pancreatic cancer is the fourth leading cause of cancer-related deaths in Europe and the United States. Surgical resection remains the only potentially curative treatment. However, the median survival of patients undergoing pancreatic resection alone is 16-23 months. The administration of adjuvant chemotherapy leads to an improvement in overall survival. Thus, completion of multimodality treatment (MMT) is the ideal goal and standard of care for treatment of pancreatic ductal adenocarcinoma (PDAC).
Currently, the surgery-first (SF) strategy is the most universally accepted approach to resectable PDAC (and is the standard of care in Norway), but the optimal sequence of surgery and chemotherapy remains unclear.
The purpose of this study is to further investigate the additional efficacy of neoadjuvant chemotherapy to the standard treatment for resectable cancer of the pancreatic head (surgery followed by adjuvant chemotherapy).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Odense, Denmark
- Per Pfeiffer
-
-
-
-
-
Helsinki, Finland, 00029
- Ville Sallinen
-
-
-
-
-
Bergen, Norway, 5021
- Haukeland University Hospital
-
Oslo, Norway, N- 0424
- Oslo University Hospital
-
Stavanger, Norway, 4011
- Stavanger University Hospital
-
Stavanger, Norway, 9038
- Tromsø University Hospital
-
Trondheim, Norway, 7030
- St. Olav University Hospital
-
-
-
-
-
Gothenburg, Sweden, 41345
- Sahlgrenska University Hospital
-
Huddinge, Sweden, 14157
- Karolinska University Hospital
-
Linköping, Sweden, 58185
- Linkoping University Hospital
-
Lund, Sweden
- Skåne University Hospital
-
Umeå, Sweden, 90737
- University Hospital of Umeå
-
Uppsala, Sweden, 75185
- Uppsala University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Resectable adenocarcinoma of the pancreatic head
- T1-3, Nx, M0 (UICC 7th version, 2010)
- Cytologic or histologic confirmation of adenocarcinoma
- Age > 18 year and considered fit for major surgery
- Written informed consent
- Considered able to receive the study specific chemotherapy
Exclusion Criteria:
- Co-morbidity precluding pancreaticoduodenectomy
- Chronic neuropathy ≥ grade 2
- WHO performance score > 2 • Granulocyte count < 1500 per cubic millimetre
- Platelet count < 100 000 per cubic millimeter
- Serum creatinine > 1.5 UNL (upper limit normal range)
- Albumin < 2,5 g/dl
- Female patients in child bearing age not using adequate contraception, pregnant or lactating women • Mental or organic disorders which could interfere with informed consent or treatments
- Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive cervical cancer
- Percutaneous tumor biopsy
- Any reason why, in the opinion of the investigator, the patient should not participate
- Pregnancy
- Breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Surgery and then postoperative adjuvant chemotherapy
|
Neoadjuvant treatment
Neoadjuvant treatment
Neoadjuvant treatment
All patients
Adjuvant treatment
Adjuvant treatment
Adjuvant treatment
|
EXPERIMENTAL: Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
|
Neoadjuvant treatment
Neoadjuvant treatment
Neoadjuvant treatment
All patients
Adjuvant treatment
Adjuvant treatment
Adjuvant treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival 18 month after randomization
Time Frame: 18 month
|
Overall survival at 18 months after date of randomization (intention to treat)
|
18 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall mortality at one year following commencement of allocated treatment.
Time Frame: 1 year
|
Overall mortality at one year following commencement of allocated treatment (NT or SF) for those who ultimately undergo resection
|
1 year
|
Disease-free survival
Time Frame: until 5 years after surgery
|
Patient will come to regular after surgery for follow-up visits regarding their disease.
|
until 5 years after surgery
|
Histopathological response
Time Frame: Arm 1: Baseline and Arm 2; 4 weeks after baseline
|
The histopathological response of the tumor to the neoadjuvant treatment will be assessed by established scores (R0 resection and (y)pN0 disease)
|
Arm 1: Baseline and Arm 2; 4 weeks after baseline
|
Complication rate after surgery
Time Frame: 30 and 90 days
|
Complication rate after surgery as measured by Dindo-Clavien/ISPGS classification systems
|
30 and 90 days
|
Feasibility of neoadjuvant and adjuvant chemotherapy
Time Frame: Baseline
|
The feasibility of neo-adjuvant and adjuvant chemotherapy measured by common Terminology Criteria for Adverse Events, grade 3-5, dose reduction and dose delay
|
Baseline
|
Health related Quality of Life
Time Frame: until 5 years after surgery
|
Data of quality of life will be assessed by the questionnaires EORTC QLQ-30
|
until 5 years after surgery
|
Health economics
Time Frame: until 5 years after surgery
|
Data of quality of life will be assessed by the questionnaires EQ-5D
|
until 5 years after surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Knut Jorgen Labori, MD PhD, Oslo University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Fluorouracil
- Oxaliplatin
- Irinotecan
Other Study ID Numbers
- NorPACT-1
- 2015-001635-21 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on 5-FU
-
Hamamatsu UniversityCompletedEsophageal Cancer | Squamous Cell CarcinomaJapan
-
Eastern Hepatobiliary Surgery HospitalCompletedHepatocellular CarcinomaChina
-
University of Sao PauloLEO PharmaCompletedSafety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic KeratosisActinic KeratosisBrazil
-
Nippon Kayaku Co., Ltd.CompletedMetastatic Colorectal Cancer | Advanced Solid TumorsUnited States
-
Fudan UniversityUnknown
-
Taian Cancer HospitalUnknownEsophageal CarcinomaChina
-
Sol-Gel Technologies, Ltd.CompletedActinic Keratosis (AK)United States
-
Eastern Hepatobiliary Surgery HospitalCompletedHepatocellular Carcinoma | Portal Vein Tumor ThrombusChina
-
Sun Yat-sen UniversityUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownSquamous Cell Carcinoma of the Head and NeckChina